N/A Completed N=39 Randomized Double-blind Treatment

Effect of Action Observation Training on Gait Variables and Global Cognitive Functions

Mild Cognitive Impairment

Source: ClinicalTrials.gov NCT03522389 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2025

Primary outcomePrimary: Gait Speed During the Single Task — 0.17; 0.09; 0.00; 0.15 m/s — p=0.003

Summary

This study will investigate the effect of Action Observation Teaining (AOT) on gait variables and global cognitive functions in older adults with mild cognitive impairment (MCI). The specific objectives are 1) to compare gait variables and global cognitive functions among the AOT with gait training, gait training, and control groups at before training, after training, and follow up and 2) to compare gait variables and global cognitive functions among before training, after training, and follow up in each of the groups.

Outcome Measures

Outcome	Result	p-value
PRIMARY Gait Speed During the Single Task	0.17; 0.09; 0.00; 0.15; 0.12; -0.01	0.003 sig
PRIMARY Gait Speed During the Dual Task	0.17; 0.12; -0.02; 0.15; 0.12; 0.04	<0.001 sig
SECONDARY Stride Time Variability During Single Task	0.06; 0.01; 0.20; -0.09; -0.05; -0.34	0.924
SECONDARY Stride Time Variability During Dual Task	-1.41; -0.38; 0.93; -1.57; -1.15; 1.20	0.161
SECONDARY Montreal Cognitive Assessment (MoCA)	2.45; 1.36; 2.27; 4.64; 2.36; 2.36	0.445

Eligibility Criteria

Inclusion Criteria

Aged 60-80 years old.
Having subjective evidence of cognitive decline from patients, or from closely informants, or from a clinicians.
Having objective evidence of cognitive decline, deﬁned by using a Montreal Cognitive Assessment (MoCA) 18-24 points.
Independent function in daily life
Independent walking without using gait aids.
Having fall risk, defined by the fall risk threshold (gait velocity 9 points.
Diagnosis as dementia by neurologists.
Any cardiac or respiratory disease that could cause gait limiting.
Musculoskeletal disorder that affected gait performance.
Balance disorder in assessment day, such as vertigo and dizziness.
Visual acuity with a glasses worse than 6/15 (metric system) in both their eyes.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03522389). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.